STOCK TITAN

CryoPort, Inc. - $CYRX STOCK NEWS

Welcome to our dedicated page for CryoPort news (Ticker: $CYRX), a resource for investors and traders seeking the latest updates and insights on CryoPort stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CryoPort's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CryoPort's position in the market.

Rhea-AI Summary
Be The Match BioTherapies and Cryoport announce strategic partnership to expand capabilities of IntegriCell solution for the global cell therapy market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
partnership
-
Rhea-AI Summary
Cryoport named 'Best Cell & Gene Therapy Supplier - Cryogenic Storage' at IMAPAC Asia Pacific Cell & Gene Therapy Excellence Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences earnings
-
Rhea-AI Summary
Cryoport, Inc. announces preliminary results for Q2 2023 and updates full year revenue expectations. Q2 revenue expected to decrease by 11% compared to last year due to weaker global demand, clinical trial delays, and slower ramps from clients. Full year 2023 revenue now expected to be in the range of $233-$243 million. Long-term outlook remains positive with the cell and gene therapy industry expected to grow at a CAGR of over 22%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
CryoPort, Inc.

Nasdaq:CYRX

CYRX Rankings

CYRX Stock Data

784.17M
44.46M
2.42%
107.67%
8.25%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BRENTWOOD

About CYRX

cryoport delivers an innovative and complete outsourced frozen shipping solution for biological materials. this breakthrough combination replaces outdated dry ice shipping, virtually eliminates the risk of cell degradation and revolutionizes deep frozen logistics. we combine the technology of liquid nitrogen dry vapor shippers with the most advanced logistics management platform in the industry. when added with our logistics expertise, we provide a complete outsourced solution that advances deep-frozen shipping for the life science community. whether your business is bio-pharmaceuticals, clinical trials, research or reproductive medicine, you want to focus on your core mission. cryoport will help you transport life.